Author

Kebing Yu

Genentech

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

Anna ShemorryiD· 1 shared Carrie R. GraveeliD· 1 shared Curt J. EssenburgiD· 1 shared Danilo MaddaloiD· 1 shared Elisia VillemureiD· 1 shared Elizabeth A. Tovar· 1 shared Elizabeth Levy· 1 shared Emily WolfrumiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anna ShemorryORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

Anna Shemorry, Willem den Besten, Melinda M. Mulvihill, Curt J. Essenburg, Nicole Blaquière, Tracy Kleinheinz, Elisia Villemure, Frank Peale, Gauri S. Deshmukh, Danilo Maddalo, Elizabeth Levy, Kebing Yu, Matthew R. Steensma, Elizabeth A. Tovar, Emily Wolfrum, , Ingrid E. Wertz

This study evaluates bifunctional ER degraders with different ubiquitin ligase ligands, finding that pan-IAP antagonists enhance ER degradation and induce TNF-dependent cell death more effectively than existing therapies.

Cell chemical biology · May 1, 2025Peer-reviewedCancer Biology